(2023) reported the case of a long duration of intracranial response to sotorasib in the second-line setting lasting 16 months in a patient with both pretreated and untreated symptomatic BMs from KRAS G12C mutant NSCLC (71). This evidence concerns the gene KRAS and non-small cell lung carcinoma.